GlassScriptPhysician profile
Jeffrey Peter Mcgovern
NPI 1780651554
$14,986.06
in general payments reported to CMS, 2019-2025
21 companies · $621 in 2025
The $621 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,602 · 2020: $206 · 2021: $86.00 · 2022: $174 · 2023: $418 · 2024: $12K · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Food and Beverage: $993 · Travel and Lodging: $912 · Consulting Fee: $900 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,024.00 |
| Food and Beverage | $992.72 |
| Travel and Lodging | $912.03 |
| Consulting Fee | $900.00 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $11,589.53 | 2019-2025 | |
| Veran Medical Technologies, INC. | $1,243.20 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $725.00 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $334.75 | 2019-2025 | Ofev, Jascayd |
| Inspire Medical Systems, INC. | $288.75 | 2023-2025 | Inspire |
| Harmony Biosciences LLC | $192.28 | 2021-2022 | |
| Avadel Cns Pharmaceuticals, LLC | $150.00 | 2024 | Lumryz |
| Eisai INC. | $125.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $59.16 | 2019-2025 | Airsupra |
| Regeneron Healthcare Solutions, INC. | $48.10 | 2019-2024 | Dupixent |
| Insmed, INC. | $43.66 | 2020-2025 | Arikayce |
| Glaxosmithkline, LLC. | $38.25 | 2019-2020 | |
| Verona Pharma, INC. | $25.78 | 2025 | Ohtuvayre |
| Axsome Therapeutics, INC. | $20.47 | 2022 | |
| Ethicon INC. | $19.88 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $16.81 | 2019 | |
| Advanced Respiratory, INC | $14.94 | 2020 | |
| Janssen Pharmaceuticals, INC | $13.26 | 2019 | |
| Circassia INC. | $12.55 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $12.51 | 2019 | |
| Genentech USA, INC. | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Mcgovern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.